NASD · Healthcare · Biotechnology · USA
Kodiak Sciences Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Kodiak Sciences develops retinal medicines using its Antibody Biopolymer Conjugate platform technology. The company's clinical programs include tarcocimab tedromer for diabetic retinopathy and wet age-related macular degeneration, KSI-501 targeting IL-6 and VEGF for retinal vascular diseases, and KSI-101 for macular edema from inflammation. Kodiak retains global rights to its product candidates.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Kodiak Sciences Inc stock.
Not valued: We cannot value this company yet.
17 more funds hold it; the full list is part of the paid plan.
135 more in this industry show a wider margin of safety.
We do not publish a verdict on KOD yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-19 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.